Wall Street Zen Downgrades Certara (NASDAQ:CERT) to Hold

Certara (NASDAQ:CERT) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Other analysts also recently issued reports about the stock. Morgan Stanley decreased their price objective on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 18th. BMO Capital Markets assumed coverage on Certara in a report on Thursday, November 13th. They set a “market perform” rating and a $9.00 price target on the stock. Stephens dropped their price objective on Certara from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, December 12th. Leerink Partners upgraded Certara from a “market perform” rating to an “outperform” rating and set a $13.00 target price for the company in a research report on Tuesday, January 6th. Finally, Barclays lowered their price target on Certara from $14.00 to $13.00 and set an “overweight” rating on the stock in a report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.82.

Certara Trading Down 0.7%

Shares of NASDAQ:CERT opened at $6.62 on Friday. The stock has a 50 day moving average of $8.82 and a 200 day moving average of $10.14. The company has a market cap of $1.05 billion, a PE ratio of 94.57 and a beta of 1.47. Certara has a 12-month low of $6.45 and a 12-month high of $15.69. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 0.27.

Institutional Trading of Certara

Several hedge funds have recently made changes to their positions in the business. First Horizon Corp purchased a new position in Certara in the third quarter worth about $30,000. Versant Capital Management Inc boosted its holdings in shares of Certara by 66.7% in the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after purchasing an additional 1,153 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in shares of Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after purchasing an additional 2,870 shares during the last quarter. Osaic Holdings Inc. increased its position in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new stake in Certara during the 2nd quarter valued at $59,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.